X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Momentum / AstraZeneca PLC (AZN.L) 20-01-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

AstraZeneca PLC (AZN.L) 20-01-20

Will shares in AstraZeneca PLC (AZN.L) continue to new highs?

 

  • The share price performance has been very strong, now trading at 7835p (at time of writing), .
  • Will we see an end to the trend, or is the momentum set to continue?
  • Could this be the ideal opportunity for those seeking a momentum play?
  • Whilst the trend has been relentless, remember that strong past performance may not always continue.
  • Technical traders should be mindful of new events, which can influence price action. Check our website and news outlets for updates.
  • Shares -0% from 12-month highs; +47% from 12 month lows.

Latest News

07:27:  AstraZeneca, the pharmaceutical group, announced that its liver cancer drug had been given ‘orphan drug’ status with the FDA in the US.

16 Jan:  Credit Suisse reiterates its outperform rating on AstraZeneca (AZN) and increased the target price to 8500p (from 8200p).

16 Jan:  Barclays Capital reiterates its overweight rating on AstraZeneca (AZN) and increased the target price to 8500p (from 8300p).

13 Jan:  AstraZeneca and Merck announced that their new drug used to treat ovarian cancer was designated for priority review by the FDA in the US.

06 Jan:  Morgan Stanley reiterates its equal weight rating on AstraZeneca (AZN) and increased the target price to 8100p (from 7400p).

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

 

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.